Treatment with CSE-1034 (Elores™) in the Management of Community Acquired Pneumonia Due to Multi Drug Resistant Pseudomonas aeruginosa

Introduction: Community acquired pneumonia (CAP) is one of the important cause of mortality and morbidity. CAP is defined as an infection of the lung parenchyma that is not acquired in a hospital, long-term care facility, or other recent contact with the health care system. Frequently, Pseudomonas aeruginosa (P. aeruginosa) is resistant to most antibiotics. This resistance is one of the main barriers in bacterial eradication and clinical cure of Pseudomonas infection. This delay in management of MDR P. aeruginosa with appropriate antibiotics, can lead to increased mortality and morbidity.

Case Presentation: Here we discuss a case of a CAP due to P. aeruginosa which clinically didn’t respond to piperacillin-tazobactam & meropenem and was resistant to both classes of antibiotics. This was successfully treated with CSE-1034 (Ceftriaxone/Sulbactam/Disodium-edetate).

Conclusion: CSE-1034 (Elores™) proved to be safe and efficacious in treatment of a hospitalized patient with CAP due to MDR P. aeruginosa.